Adage Capital Partners
INO icon

Adage Capital Partners’s Inovio Pharmaceuticals INO Stock Holding History

Adage Capital Partners’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-804,958
Closed -$1.4M – 1043
2026
Q1 		$1.4M Sell
804,958
-1,748,613
-68% -$2.88M ﹤0.01% 862
2025
Q4 		$4.44M Sell
2,553,571
-875,000
-26% -$1.93M 0.01% 775
2025
Q3 		$8.02M Buy
+3,428,571
New +$6.56M 0.01% 671
2020
Q4 		– Sell
-41,667
Closed -$5.8M – 853
2020
Q3 		$5.8M Buy
+41,667
New +$8.69M 0.01% 611

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners's INO Position: Q2 2026 in Review

Adage Capital Partners sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 804,958 shares — an estimated $1.4M sold.

Adage Capital Partners first reported a position in INO in Q3 2020 and held it in 4 quarters. The position peaked at $8.02M in Q3 2025. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • Adage Capital Partners reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Adage Capital Partners sold 804,958 Inovio Pharmaceuticals shares in Q2 2026, an estimated $1.4M.
  • Adage Capital Partners first reported a position in Inovio Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Adage Capital Partners's Inovio Pharmaceuticals position peaked at $8.02M in Q3 2025.
  • 103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.